Journal of Chemistry

Journal of Chemistry / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 8693614 | 10 pages | https://doi.org/10.1155/2019/8693614

Development of New Multicomponent Reactions in Eco-Friendly Media-Greener Reaction and Expeditious Synthesis of Novel Bioactive Benzylpyranocoumarins

Academic Editor: Alessandro Volonterio
Received21 Feb 2019
Revised02 Apr 2019
Accepted11 Jul 2019
Published21 Aug 2019

Abstract

Multicomponent cyclocondensation of hydrazine derivatives, ethyl acetoacetate, aromatic aldehydes, and 4-hydroxycoumarin has been reported. The optimization details of the developed novel protocol are recorded. The novel procedure features short reaction time, moderate yields, and simple workup. In addition, BMIM[triflate] was chosen as a green solvent. The structures of the obtained benzylpyrazolyl coumarins were determined and confirmed by 1H NMR, 13C NMR, IR, and elemental analysis. The MIC values of benzylpyrazolyl coumarin derivatives were determined by the microbroth dilution method using 96-well plates. However, the derivatives 5a, 5b, 5d, and 5g possess the strongest activities. Compound 5b was the most active derivative against Candida albicans. Moreover, the antioxidant activity determination of these coumarins derivatives 5(ag)–6(ag) were studied with the DPPH and compared with gallic acid (GA)and butylated hydroxytoluene (BHT). Molecular modelling studies using DFT (density functional theory) calculations showed that there two tautomers A and B in which A is more stable than B. The benzylpyrazolyl coumarin derivatives 5e and 6f exhibited the most cytotoxic effect on the promising cytotoxic activity with IC50 values 4.45 μg/mL against MDA-MB-231 and 4.85 μg/mL against MCF7, respectively.

1. Introduction

Coumarin scaffolds are commonly bioactive compounds [123]. Pyrazolone derivatives also exhibit a broad spectrum of biological activities [2426] and are also important structural moieties in many drug substances of medicinal applications [22, 27, 28], such as phenazone, propyphenazone, ampyrone, and metamizole sodium (Figure 1).

Multicomponent reactions convert three or more starting materials in one pot to a highly functionalized product displaying maximum molecular diversity [2935].

At present, ionic liquids (ILs) are playing a more and more important role in organic synthesis as green catalysts and solvents. Compared with traditional catalysts, these ionic liquids have shown special advantages and potential due to their ideal catalytic performance and the unusual characteristics.

Here, we report the synthesis of pyrazolone-linked coumarin derivatives which were obtained via the four-component domino reaction of 4-hydroxycoumarin, hydrazine derivatives, ethyl acetoacetate, and arylaldehydes; then, the structures of these new coumarin derivatives were characterized by spectroscopic methods (1H and 13C NMR, FT-IR, and elemental analysis). In addition, the benzylpyrazolyl coumarin derivatives were tested for their antimicrobial and antioxidant activities, which have not been studied in the past.

2. Results and Discussion

The cyclocondensation of hydrazine derivatives, ethyl acetoacetate, and arylaldehydes with 4-hydroxycoumarins to generate benzylpyrazolyl coumarin derivatives was investigated under a variety of conditions (solvents, reaction time, temperature, and catalysts) (Scheme 1).

Initially, for examination of the catalytic activity, different catalysts such as TFA, HCOOH, Cu(OAc)2, ZnO, and glacial acetic acid were selected. Then, a model study was carried out by the condensation reaction of hydrazine derivatives, ethyl acetoacetate, aromatic aldehydes, and 4-hydroxycoumarin under conventional conditions at different temperatures in the presence of each catalyst, separately. The corresponding results are summarized in Table 1.



EntryCatalysts (mmol%)SolventTime (h)Temperature (°C)Yielda,b,c (%)

1No([BMIM][CF3SO3])24210
2NoDMC2490
3NoH2O24100
4NoEtOH2478
5NoCH3CN2482
6NoTHF2466
7NoCH2Cl22440
8NoToluene24110
9NoGlacial AcOH24119
10TFA (10)([BMIM][CF3SO3])2421040
11HCOOH (10)([BMIM][CF3SO3])2421045
12Cu(OAc)2 (10)([BMIM][CF3SO3])24210
13ZnO (10)([BMIM][CF3SO3])24210Trace
14Gl. AcOH (5)([BMIM][CF3SO3])2421065
15Gl. AcOH (10)([BMIM][CF3SO3])2421095
16Gl. AcOH (15)([BMIM][CF3SO3])2421094
17Gl. AcOH (20)([BMIM][CF3SO3])2421085
18Gl. AcOH (10)([BMIM][CF3SO3])30 min21095
19Gl. AcOH (10)([BMIM][CF3SO3])40 min21085
20Gl. AcOH (10)([BMIM][CF3SO3])121076
21Gl. AcOH (10)([BMIM][CF3SO3])1 : 5 h21072
22Gl. AcOH (10)([BMIM][CF3SO3])221075

aAll reactions were carried with hydrazine (0.005 mol), ethyl acetoacetate (0.005 mol), benzaldehyde (0.005 mol), and 4-hydroxycoumarin (0.005 mol). bYield of the isolated product. cThe reaction failed to provide a product. [BMIM][CF3SO3], 1-butyl-3-methylimidazolium trifluoromethanesulfonate.

Several catalysts were tested to check their effects such as TFA, HCOOH, Cu(OAc)2, ZnO, and glacial acetic acid (Table 1, entries 1015). The obtained results indicated that glacial AcOH is the best catalyst for this reaction. Then, several amounts of this catalyst were evaluated: It was found that 5 mol% of the catalyst gave 65% of yield. When we increased the amounts of the catalyst to 10 mol%, 15 mol%, and 20 mol%, the yields were also found to be increased up to 95%, 94%, and 85%, respectively. After 20 mol%, there is no significant improvement of the yield of the reaction; consequently, 10 mol% of the catalyst was chosen as the maximum quantity of the catalyst for the reaction. The reaction was also performed at different reaction times, and the obtained results showed that the best reaction time was 30 min (Table 1, entries 1 and 1517). Based on all of these experiments, the optimum reaction conditions were identified as [BMIM][CF3SO3] for 30 min using 10 mmol% of glacial acetic acid. The reaction was then carried out with different series of substituted aromatic aldehydes in order to check the limitations of this methodology. The results are summarized in Table 2.



EntryRCompoundbYielda (%)Melting point (°C)

1H5a60204
2p-CH35b70221
3p-N(CH3)25c75176
4p-NO25d80138
5m-Br5e75242
6m-OCH35f85138
7m-OH5g90174

aAll reactions were carried with hydrazine (0.005 mol), ethyl acetoacetate (0.005 mol), benzaldehyde (0.005 mol), and 4-hydroxycoumarin (0.005 mol). bYield of the isolated product. [BMIM][CF3SO3], 1-butyl-3-methylimidazolium trifluoromethanesulfonate.

The aromatic aldehydes carrying both electron-withdrawing and electron-donating functional groups (Table 2, entries 27) underwent successful condensation with ethyl acetoacetate and hydrazines derivatives. The structures of compound 5 were confirmed from their spectroscopic data including 1H NMR, 13C NMR spectra, and elemental analysis.

In the 1H NMR of compound 5c, two characteristic singlets at 3.34 and 3.55 ppm were assigned to the methyl protons (a) and (b, d), whereas the proton Hc appears as a singlet at about 4.17 ppm in accordance with the literature data for other 4-hydroxycoumarin derivatives [36, 37]. 13C NMR showed the C2′ signal at δ = 168.06 ppm, the C4 signal had a chemical shift of δ = 164.90 ppm, while the C2, C3, Ca, Cc, Cb,d, C1, and C5 signals were assigned at δ = 162.87, 103.59, 13.66, 36.34, 40.01, 128.53, and 152.9 ppm, respectively.

The compound 5 thus obtained can exist in the form of two tautomers A and B. Theoretical calculations with the Gaussian program 09 carried out with the DFT (density functional theory) level with the base 6-31G + (d) and the functional B3LYP confirm the stability of the structure A with respect to that of BE = 2 kcal). Optimized geometries for compounds A and B are shown in Figure 2.

Encouraged by the obtained results, we tried to extrapolate our method to the condensation with hydrazine. The reaction seemed to be tolerant with different aromatic aldehydes. Overall, yields in the range of 75%–95% were obtained (Table 3).



EntryRCompoundYield (%)Melting point (°C)

1H6a95120
2p-CH36b75142
3p-N(CH3)26c80160
4p-NO26d85210
5m-Br6e87160
6m-OCH36f90236
7m-OH6g95240

The structure of the benzylpyrazolyl coumarin 6 derivatives has been confirmed by their spectroscopic data, and their melting points are compared with literature reports. The presence of signal at 3425 cm−1 in IR spectra was assigned to NH.

3. Antimicrobial Activity

The in vitro antimicrobial activity of the novel benzylpyrazolyl coumarin derivatives 5(ag)–6(ag) were evaluated for in vitro antimicrobial activity by the well diffusion method. All products were screened for activity against Gram-positive bacteria (Micrococcus luteus, Listeria monocytogenes, and Staphylococcus aureus), Gram-negative bacteria (Pseudomonas aeruginosa and Escherichia coli), and fungi (Candida albicans). The minimum inhibitory concentrations (MICs) were determined and are given in Table 4.


CompoundsMicroorganisms
Micrococcus luteus LB 14110Listeria monocytogenes ATCC 19117Staphylococcus aureus ATCC 6538Pseudomonas aeruginosa ATCC 49189E. coliCandida albicans

5a24 ± 0.125 ± 0.1
5b12 ± 0.216 ± 0.518 ± 0.426 ± 0.5
5c20 ± 0.116 ± 0.120 ± 0.2
5d12 ± 0.515 ± 0.118 ± 0.3
5e10 ± 0.212 ± 0.520 ± 0.620 ± 0.6
5f10 ± 0.214 ± 0.220 ± 0.322 ± 0.2
5g14 ± 0.516 ± 0.418 ± 0.2
6a15 ± 0.430 ± 0.128 ± 0.4
6b15 ± 0.228 ± 0.228 ± 0.5
6c10 ± 0.214 ± 0.224 ± 0.1220 ± 0.6
6d15 ± 0.224 ± 0.326 ± 0.3
6e22 ± 0.512 ± 0.3
6f14 ± 0.324 ± 0.415 ± 0.228 ± 0.1
6g18 ± 0.316 ± 0.520 ± 0.222 ± 0.324 ± 0.328 ± 0.2

As can be seen, most of the benzylpyrazolyl coumarin derivatives exhibit considerable activity against the tested microorganisms. The results obtained by these tests showed that our different molecules have antimicrobial activity. In fact, regarding the activity against Gram-negative bacteria (Pseudomonas aeruginosa), 5a showed excellent activity and compounds 5b5g showed good activity. On the contrary, compound 5b was the most active against Candida albicans.

In addition, we evaluated the antimicrobial activity of four synthetic products (5a, 5b, 5d, and 5g) possessing the strongest activities against two Gram-positive bacteria (S. aureus) and Gram-negative bacteria (P. aeruginosa) against a fungus (Candida albicans) by the determination of the MIC in a liquid medium.

We determined the MIC values of the products tested against two bacteria and a fungus. Then, the minimal inhibitory concentration (MIC) values of benzylpyrazolyl coumarin derivatives were determined against Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 49189, and Candida albicans. The obtained results are given in Table 5.


MicroorganismsCompounds
6a6b6g5aAmpicillinFluconazole

Staphylococcus aureus ATCC 65380.31250.31250.15620.6250.04
Pseudomonas aeruginosa ATCC 491890.15620.31250.6250.6250.04
Candida albicans0.009750.0390.07810.009750.00125

We have noticed that the compounds 6a, 6b, and 6g are very active by comparing with ampicillin used as a control antibiotic against the strain Staphylococcus aureus. These same results showed that the compounds 6a and 5a are very active against the fungus Candida albicans by comparing with a standard antifungal “fluconazole.”

4. Antioxidant Activities

The scavenging activity of the synthesized benzylpyrazolyl coumarin derivatives 5 with DPPH (1,1-diphenyl-2-picrylhydrazyl) was investigated (Figure 3).

The analysis of the results showed that the profiles of the antiradical activity obtained reveal that the synthetic products tested compound 5 have a very important antiradical activity. For a used concentration (0.0625 mg/ml), the product 5e has a radical activity lower than gallic acid and BHT (butylated hydroxytoluene). Of the same way, the compound 5b for a concentration equal to 0.01575 mg/ml has a lower radical activity than gallic acid and BHT (butylated hydroxytoluene). At a concentration of 1 mg/ml, these products revealed a very interesting activity of DPPH in comparison with the activity of the synthetic antioxidants used.

5. Conclusion

In this study, the synthesis of pyrazolone-linked coumarin derivatives through a four-component, one-pot condensation of ethyl acetoacetate, aromatic aldehydes, hydrazines, and 4-hydroxycoumarin using ([BMIM][CF3SO3]) as a green solvent was described. In addition, their structures were confirmed by elemental and spectral analyses. The antibacterial and antioxidant property of the synthesized compounds were assessed against Gram-positive and Gram-negative bacteria. Some of the compounds were very effective as antimicrobial agents. The results of the research were promising, and some of the synthesized derivatives represent good candidates for MIC determination during future studies. This study further presents benzylpyrazolyl coumarin derivatives as a new class of antioxidant agents, and it may serve as a model compound for design and development of therapeutic-based anticancer inhibitors.

6. Experimental

6.1. General Information

All manipulations were performed using Standard Schlenk techniques under the Argon atmosphere. Chemicals were purchased from Sigma-Aldrich and were used without further purification. All solvents were purified and dried by the MBRAUN SPS 800 solvent purification system. 1H NMR and 13C NMR spectra were recorded at 400 MHz and 100 MHz, respectively. Chemical shifts, δ, are reported in ppm relative to the internal standard TMS for both 1H and 13C NMR. The products were characterized by GC (gas chromatography). Quantitative GC analyses were performed with the GC-2010 Plus gas chromatography (SHIMADZU). The NMR studies were carried out in high-quality 5 mm NMR tubes. Signals are quoted in parts per million as δ downfield from tetramethylsilane (δ = 0.00) as an internal standard. NMR multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, and m = multiplet signals. IR spectra were recorded on a 398 spectrophotometer.

Elemental microanalysis was performed on an Elementar Vario El III Carlo Erba 1108 elemental analyzer, and the values found were within ±0.4% of the theoretical values. Melting points were determined with the Kofler bench. The biological analysis was done regarding our previous work [36, 37].

6.2. General Procedure for the Synthesis of Coumarin Derivatives 5(ag)–6(ag)

A mixture of hydrazine (5 mmol, 0.157 mL) or phenylhydrazine 1 (5 mmol, 0.491 mL), ethyl acetoacetate 2 (5 mmol, 0.6 mL), aromatic aldehyde 3 (benzaldehyde (5 mmol, 0.510 mL), para tolyl benzaldehyde (5 mmol, 0.589 mL), 4-(dimethylamino)benzaldehyde (5 mmol, 0.745 g), 4-nitrobenzaldehyde (5 mmol, 0.755 g), 3-bromobenzaldehyde (5 mmol, 0.582 mL), m-anisaldehyde (5 mmol, 0.609 mL), 3-hydroxybenzaldehyde (5 mmol, 0.610 g)), 4-hydroxycoumarin 4 (5 mmol, 0.810 g), and glacial acetic acid (10 mmol%, 0.02 mL) in 5 ml of ionic liquid [BMIM][CF3SO3] was stirred at 210°C. After completion of the reaction (indicated by TLC), the reaction mixture was then cooled to the room temperature to give a precipitate, and the free-flowing solid was filtered and washed with water. The precipitated crude product was purified by recrystallization from hot ethanol. The isolated compounds were well characterized by IR, 1H NMR, 13C NMR, and elemental analysis.

6.2.1. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(phenyl)methyl)-5-methyl-l-2-phenylpyrazol-3-one (5a)

Yield: 1.72 g (60%); m.p. 204°C–206°C; 1H NMR (DMSO-d6, 400 MHz): δ 2.42 (s, 3H, Ha), 5.74 (s, 1H, H4′), 6.38 (s, 1H, Hc), 7.21 (s, 1H, H9′), 7.31 (m, 2H, H2”,6″), 7.35 (m, 3H, H3″,4″,5″), 7.43 (d, 2H, H6,8), 7.51 (m, 2H, H8′,10′), 7.62 (m, 2H, H7′,11′), 7.87 (d, 1H, H7), 7.89 (d, 1H, H5); 13C NMR (DMSO-d6, 100 MHz,): δ 34.14 (Ca), 39.60 (Cc), 104.46 (C3), 105.95 (C1′), 107.18 (C8), 116.36 (C7′), 118.50 (C11′), 121.29 (C9′), 124.31 (C5), 126.48 (C6), 127.26 (C4″), 128.68 (C2″), 129.73 (C3″), 132.42 (C7), 135.59 (C8′), 139.93 (C10′), 147.44 (C6′), 152.45 (C1″), 162.69 (C10), 163.98 (C2), 164.74 (C4), 165.31 (C2′); Anal. Calc. C26H20N2O4: C, 73.573%; H, 4.749%; N, 6.600%; Found: C, 73.9; H, 4.5; N, 6.8%.

6.2.2. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)-(p-tolyl)methyl)-5-methyl-2-phenylpyrazol-3-one (5b)

Yield: 1.53 g (70%); m.p. 221°C–223°C; IR (cm−1) 3585 (O-H), 3425 (NH), 1542 (C=C), 1715 (CO lactone), 1742 (CO ketone); δ 2.24 (s, 3H, Ha), 2.40 (s, 3H, Hb), 3.17 (s, 1H, H4′), 5.67 (s, 1H, Hc), 7.01 (s, 2H, H3″,5″), 7.06 (s, 2H, H2″,6″), 7.30 (m, 3H, H6,8′,10′), 7.52 (t, 1H, H8), 7.58 (m, 2H, H7′,9′), 7.68 (d, 1H, H11′), 7.79 (dd, 1H, H7), 7.86 (dd, 1H, H5); 13C NMR (DMSO-d6, 100 MHz): δ 20.91 (Cb), 33.81 (Ca), 39.72 (Cc), 104.73 (C3), 106.16 (C1′), 107.3 (C8), 116.3 (C11′), 121.19 (C9′), 124.25 (C5), 127.16 (C6), 129.24 (C7), 129.70 (C3″), 132.29 (C2″), 135.39 (C8′), 136.80 (C4″), 147.39 (C1″), 152.42 (C6′), 162.74 (C5′), 163.84 (C10), 164.70 (C2), 165.33 (C4), 165.72 (C2′); Anal. Calc. for C27H22N2O4: C, 73.9%; H, 5.0%; N, 6.3%; Found: C, 73.5; H, 6.1; N, 6.2%.

6.2.3. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)-(p-N,N-dimethyl phenyl)methyl)-5-methyl-2-phenylpyrazol-3-one (5c)

Yield: 75 g (75%); m.p. 176°C–178°C; IR (cm−1) 3585 (O-H), 3425 (NH), 1542 (C=C), 1715 (CO lactone), 1745 (CO amide); 1H NMR (DMSO-d6, 400 MHz): δ 3.34 (s, 3H, Ha), 3.55 (s, 6H, Hb,d), 4.17 (s, 1H, Hc), 7.32 (s, 1H, H3″), 7.88 (d, 1H, H5″), 8.20 (t, 2H, H2″,6″), 8.33 (m, 2H, H6,8), 8.46 (t, 1H, H9′), 8.56 (t, 2H, H8′,10′), 8.62 (s, 2H, H7′,11′), 8.86 (dd, 1H, H7), 9.00 (dd, 1H, H5), 9.68 (s, 1H, H4); 13C NMR (DMSO-d6, 100 MHz): δ 36.34 (Ca), 39.59 (Cb,), 103.59 (C3), 111.80 (C1′), 116.0 (C2″), 118.58 (C8), 120.2 (C7′), 121.68 (C9′), 123.42 (C5), 124.56 (C6), 128.53 (C3″), 129.15 (C5″), 131.53 (C7), 137.89 (C8′), 139.36 (C1″), 148.61 (C6′), 152.0 (C4″), 152.99 (C5′), 154.28 (C10), 162.87 (C2), 164.90 (C4), 168.06 (C2′); Anal. Calc. for C28H25N3O4: C, 71.93%; H, 5.39%; N, 8.9%; Found: C, 71.7%; H, 5.4%; N, 8.7%.

6.2.4. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-nitrophenyl)methyl)-5-methyl-2-phenylpyrazol-3-one (5d)

Yield: 1.87 g (80%); m.p. 138°C–140°C. IR (cm−1) 3585 (O-H), 3425 (NH), 1540 (C=C), 1715 (CO lactone), 1742 (CO amide); 1H NMR (DMSO-d6, 400 MHz): δ 1.06 (s, 3H, Ha), 3.44 (s, 1H, H4′), 6.35 (s, 1H, Hc), 6.84 (s, 1H, H9′), 7.16 (d, 2H, H6,8), 7.27 (m, 1H, H8′), 7.37 (m, 1H, H10′), 7.53 (m, 1H, H2″), 7.69 (d, 1H, H6″), 7.82 (d, 1H, H7′), 7.89 (d, 1H, H11′), 7.94 (s, 1H, H7), 8.05 (d, 1H, H5), 8.13 (d, 1H, H3″), 8.22 (m, 1H, H5″), 10.89 (s, 1H, H4); 13C NMR δ (DMSO-d6, 100 MHz): δ 34.87 (Ca), 39.82 (Cc), 103.60 (C3), 105.00 (C1′), 106.78 (C8), 113.03 (C7′), 116.22 (C11′), 120.37 (C9′), 121.46 (C5), 124.48 (C7), 126.43 (C3″), 129.67 (C6), 134.05 (C2″), 143.07 (C6″), 144.90 (C7), 146.44 (C8′), 147.30 (C10′), 148.46 (C6′), 151.05 (C4″), 152.55 (C5′), 152.95 (C10), 162.24 (C2), 164.89 (C4), 167.42 (C2′); Anal. Calc. for C26H19N3O6: C, 66.5%; H, 4.0%, N, 8.9%; Found C, 66.4%; H, 4.2%; N, 8.8%.

6.2.5. 4-((3-Bromo-phenyl)-(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)-5-methyl-1,2-dihydro-5-methyl-2-phenylpyrazol-3-one (5e)

Yield: 88 g (75%); m.p. 242°C–244°C. 1H NMR (DMSO-d6, 400 MHz): δ 240 (s, 3H, Ha), 3.43 (s, 1H, H4′), 5.71 (s, 1H, Hc), 7.22–7.80 (m, 13H, Harom); 13C NMR δ (DMSO-d6, 100 MHz): δ 34.03 (Ca), 39.72 (Cc), 105.10 (C3), 106.75 (C1′), 116.41 (C8), 121.38 (C7′), 122.14 (C9′), 124.35 (C6), 126.62 (C6″), 127.24 (C7), 129.75 (C8′), 130.86 (C5″), 132.52 (C2″), 135.59 (C6′), 143.16 (C1″), 147.38 (C5′), 152.50 (C10), 162.12 (C2), 164.61 (C4), 166.12 (C2′); Anal. Calc. for C26H19BrN2O4: C, 62.04%; H, 3.805%; N, 5.565%; Found: C, 62.1; H, 3.9; N, 5.6%.

6.2.6. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(3-methoxyphenyl)methyl)-5-methyl-2-phenylpyrazol-3-one (5f)

Yield: 1.92 g (85%); m.p. 138°C–140°C: 1H NMR (DMSO-d6, 400 MHz): δ 2.39 (s, 3H, Ha), 3.66 (s, 3H, Hb), 5.68 (s, 1H, Hc), 6.71 (s, 1H, H4′), 6.78 (d, 2H, H2″,6″), 7.26 (m, 5H, H6,8,9′,5″,4″), 7.51 (m, 2H, H8′,10′), 7.59 (t, 1H, H7), 7.71 (d, 2H, H7′,11′), 7.83 (t, 1H, H5); 13C NMR δ (DMSO-d6, 100 MHz): δ 33.66 (Ca), 39.86 (Cc), 54.83 (Cb), 105.21 (C3), 106.43 (C1′), 110.42 (C4″), 113.48 (C2″), 115.85 (C8), 118.19 (C6″), 119.23 (C7′), 120.75 (C9′), 123.76 (C5), 126.55 (C6), 129.71 (C7), 131.86 (C8′), 135.35 (C5″), 141.42 (C6′), 146.94 (C1″), 151.98 (C10,), 159.20 (C3″), 161.76 (C2), 163.83 (C4), 164.25 (C2′); IR (cm−1) 3588 (O-H), 3425 (NH), 1542 (C=C), 1715 (CO lactone), 1742 (CO amide); Anal. Calc. for C27H22N2O5: C, 71.3%; H, 4.8%; N, 6.1%; Found: C, 71.5; H, 5.1; N, 5.8%.

6.2.7. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)-(3-hydroxyphenyl)methyl)-5-methyl-2-phenylpyrazol-3-one (5g)

Yield: 1.98 g (90%); m.p. 174°C–176°C; IR (cm−1) 3585 (O-H), 3425 (NH), 1535 (C=C), 1710 (CO lactone), 1745 (CO amide); 1H NMR (DMSO-d6, 400 MHz): δ 22.41 (s, 3H, Ha), 3.44 (s, 1H, H4′), 5.66 (s, 1H, Hc); 6.57 (s, 1H, H9′), 6.76 (m, 2H, H4″,5″), 6.97 (d, 2H, H2″,6″), 7.30 (m, 2H, H6,8), 7.37 (m, 2H, H8′,10′), 7.68 (d, 2H, H7′,11′), 7.79 (d, 1H, H7), 7.84 (t, 1H, H5);13C NMR (DMSO-d6, 100 MHz): δ 33.61 (Ca), 39.56 (Cc), 33.61 (C3), 105.65 (C1′), 112.9 (C4″), 114.7 (C2″), 116.4 (C8), 120.3 (C6″), 121.1 (C7′), 122.8 (C9′), 123.3 (C5), 125.4 (C6), 130.1 (C5″), 137.3 (C6′), 143.7 (C1″), 152.3 (C5′), 157.35 (C3″), 162.7 (C2), 163.57 (C4), 164.34 (C2′); Anal. Calc. for C26H20N2O5: C, 70.9%; H, 4.5%; N, 6.3%; Found: C, 71.8%, H, 4.6%; N, 6.4%.

6.2.8. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)phenyl)methyl)-5-methyl-pyrazol-3-one (6a)

Yield: 95%; m.p. 120°C–122°C; IR (cm−1) 3589 (O-H), 3423 (NH), 1539 (C=C), 1705 (CO lactone), 1741 (CO amide); 1H NMR (DMSO-d6, 400 MHz): δ 2.50 (s, 3H, Ha), 6.32 (s, 1H, Hc), 7.14 (d, 3H, H3″,4″,5″), 7.18 (d, 2H, H2″,6″), 7.31 (m, 2H, H6,8), 7.56 (t, 2H, H5,7), 7.85 (d, 2H, H3′,4′); 13C NMR (DMSO-d6, 100 MHz): δ 36.42 (Ca); 39.96 (Cc), 104.74 (C3), 116.51 (C1′), 117.99 (C8), 124.34 (C5), 126.19 (C6), 127.18 (C2″), 128.61 (C3″), 132.55 (C1″), 139.86 (C10), 152.62 (C2′), 165.31 (C2), 165.39 (C4); Anal. Calc. for C20H16N2O4: C, 68.9%; H, 4.6%; N, 8.0%; Found: C, 68.9%, H, 4.6%; N, 8.0%.

6.2.9. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(p-tolyl)methyl)-5-methyl-pyrazol-3-one (6b)

Yield: 75%; m.p. 142°C–144°C; IR (cm−1) 3440 (O-H), 3423 (NH), 1539 (C=C), 1741 (CO lactone), 1797 (CO amide); 1H NMR (DMSO-d6, 400 MHz): δ 2.76 (s, 6H, Ha,b), 6.55 (s, 1H, Hc), 7.27 (s, 4H, H2′,3′,5′,6′), 7.59 (m, 4H, H5,6,7,8), 7.84 (t, 1H, H4′), 8.13 (d, 1H, H3′); 13C NMR (DMSO-d6, 100 MHz): δ 20.53 (Ca); 35.61 (Cb); 39.52 (Cc); 104.44 (C3), 116.07 (C1′), 117.46 (C8), 123.85 (C5), 126.64 (C6), 128.78 (C2″), 132.11 (C1″), 134.69 (C4″), 136.10 (C10), 152.13 (C2′), 164.66 (C2), 164.94 (C4); Anal. Calc. for C21H18N2O4: C, 69.6%; H, 5.0%; N, 7.7%; Found: C, 69.9%, H, 5.0%; N, 7.7%.

6.2.10. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-N,N-dimethylphenyl)methyl)-5-methyl-pyrazol-3-one (6c)

Yield: 80%; m.p. 160°C–162°C; IR (cm−1) 3584 (O-H), 3420 (NH), 1545 (C=C), 1715 (CO lactone), 1735 (CO amide), 1H NMR (DMSO-d6, 400 MHz): δ 3.03 (s, 3H, Ha), 3.11 (s, 6H, Hb,d), 6.28 (s, 1H, Hc), 6.82 (s, 1H, H4′), 6.82 (s, 1H, H4′), 7.29(m, 4H, H2″,3″,5″,6″), 7.52 (t, 2H, H6,8), 7.71 (d, 1H, H7), 7.80 (d, 1H, H5), 8.56 (s, 1H, H3′); 13C NMR (DMSO-d6, 100 MHz): δ 26.91 (Ca), 36.38 (Cb), 45.69 (Cc), 103.56 (C3), 112.37 (C1″), 116.02 (C2″), 120.17 (C8), 123.45 (C5), 124.57 (C7), 128.59 (C1″), 131.57 (C4″), 152.99 (C10), 159.56 (C4′), 164.91 (C2), 168.07 (C4); Anal. Calc. for C22H21N3O4: C, 67.5%; H, 5.4%; N, 10.7%; Found: C, 67.5%, H, 5.4%; N, 10.7%.

6.2.11. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(4-nitrophenyl)methyl)-5-methyl-pyrazol-3-one (6d)

Yield: 85%; m.p. 210°C–212°C; IR (cm−1) 3585 (O-H), 3425 (NH), 1545 (C=C), 1712 (CO lactone), 1745 (CO amide); 1H NMR (DMSO-d6, 400 MHz): δ 2.50 (s, 3H, Ha), 3.43 (s, 1H, H4′), 6.36 (s, 1H, Hc), 7.29 (m, 4H, H6,8,2″,6″), 7.39 (d, 1H, H7), 7.54 (t, 1H, H5), 7.82 (d, 2H, H3″,5″), 8.06 (d, 1H, HH3′); 13C NMR (DMSO-d6, 100 MHz): δ 37.20 (Ca), 40.00 (Cc), 103.46 (C3), 116.17 (C1′), 119.64 (C8), 123.70 (C5), 124.58 (C2″), 128.41 (C6), 131.91 (C4″), 145.86 (C1″), 151.35 (C10), 152.96 (C2′), 164.49 (C1′), 167.68 (C4); Anal. Calc. for C20H15N3O6: C, 61.0%; H, 3.8%; N, 10.6%; Found: C, 61.0%, H, 3.8%; N, 10.6%.

6.2.12. 4-((3-Bromo-phenyl)-(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)-5-methyl-1,2-dihydro-5-methyl-pyrazol-3-one (6e)

Yield: 87%; m.p. 160°C–162°C; IR (cm−1) 3592 (O-H), 3425 (NH), 1543 (C=C), 1715 (CO lactone), 1745 (CO amide); 1H NMR (DMSO-d6, 400 MHz): δ 2.53 (s, 3H, Ha), 5.52 (s, 1H, H3′), 6.42 (s, 1H, Hc), 7.50(m, 4H, H6,8,5″,6″), 7.79(m, 3H, H7,2″,4″), 7.92(d, 1H, H5), 8.00 (d, 1H, H3′); 13C NMR (DMSO-d6, 100 MHz): δ 22.30 (Ca), 40.01 (Cc), 91.46 (C3), 114.28 (C1′), 116.84 (C9), 117.1 (C8), 123.65 (C3″), 125.63 (C5), 128.73 (C6), 131.37 (C6″), 132.19 (C7), 153.07 (C2″), 153.98 (C1″), 156.13 (C10), 158.05 (C2′), 162.31 (C2), 166.0824 (C4); Anal. Calc. for C20H15N2O4Br: C, 56.2%; H, 3.5%; N, 6.5%; Found: C, 56.2%, H, 3.5%; N, 6.5%.

6.2.13. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(3-methoxyphenyl)methyl)-5-methyl-pyrazol-3-one (6f)

Yield: 90%; m.p. 236°C–238°C; IR (cm−1) 3585 (O-H), 3425 (NH), 1535 (C=C), 1710 (CO lactone), 1735 (CO amide); δ 2.51 (s, 3H, Ha), 3.64 (s, 3H, Hb), 6.31 (s, 1H, Hc), 6.66 (d, 2H, H4″,6″), 7.14 (t, 1H, H2″), 7.35 (m, 3H, H6,8,5″), 7.58 (t, 2H, H5,7), 7.88 (d, 2H, H3′,4′); 13C NMR (DMSO-d6, 100 MHz): δ 36.42 (Ca), 39.97 (Cc), 55.33 (Cb), 104.62 (C3), 110.74 (C1′), 113.73 (C2″), 116.46 (C8), 118.2 (C6″), 119.63 (C5), 124.27 (C6), 124.35 (C7), 129.57 (C5″), 132.43 (C1″), 141.96 (C10), 152.65 (C2′), 159.73 (C3′), 165.29 (C2), 165.60 (C4); Anal. Calc. for C21H18N2O5: C, 66.6%; H, 4.7%; N, 7.4%; Found: C, 66.5%, H, 4.8%; N, 7.5%.

6.2.14. 1,2-Dihydro-4-((4-hydroxy-2-oxo-2H-chromen-3-yl)(3-hydroxyphenyl)methyl)-5-methyl-pyrazol-3-one (6g)

Yield: 95%; m.p. 204°C–206°C; IR (cm−1) 3588 (O-H), 3425 (NH), 1545 (C=C), 1715 (CO lactone), 1742 (CO amide); δ 2.51 (s, 3H, Ha), 6.31 (s, 1H, Hc), 6.66 (d, 2H, H4″,6″), 7.14 (t, 1H, H2″), 7.35 (m, 3H, H6,8,5″), 7.58 (t, 2H, H5,7),7.88 (d, 2H, H3′,4′); 13C NMR (DMSO-d6, 100 MHz): δ 36.4 (Ca), 39.9 (Cc), 104.6 (C3), 110.7 (C1′), 113.7 (C4″), 114.3 (C2″), 116.4 (C8), 120.3 (C6″), 123.7 (C5), 128.3 (C7), 152.1 (C5′), 156.9 (C3″), 157.3 (C2′), 165,2 (C2), 165,4 (C4); Anal. Calc. for C20H16N2O5: C, 65.9%; H, 4.4%; N, 7.6%; Found: C, 65.9%, H, 4.4%; N, 7.6%.

Data Availability

Data are available on request to the corresponding author.

Conflicts of Interest

The authors declare that there are no conflicts of interest.

Acknowledgments

The authors gratefully acknowledge the Qassim University, represented by the Deanship of Scientific Research, on the material support for this research under the number 3387-alrasscac-2018-1-14-S during the academic year 1440/2019 AD.

References

  1. X. Y. Huang, Z. J. Shan, H. L. Zhai, L. Su, and X. Y. Zhang, “Study on the anticancer activity of coumarin derivatives by molecular modeling,” Chemical Biology & Drug Design, vol. 78, no. 4, pp. 651–658, 2011. View at: Publisher Site | Google Scholar
  2. M. Musa, J. Cooperwood, and M. O. Khan, “A review of coumarin derivatives in pharmacotherapy of breast cancer,” Current Medicinal Chemistry, vol. 15, no. 26, pp. 2664–2679, 2008. View at: Publisher Site | Google Scholar
  3. P. O. Patil, S. B. Bari, S. D. Firke, P. K. Deshmukh, S. T. Donda, and D. A. Patil, “A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease,” Bioorganic & Medicinal Chemistry, vol. 21, no. 9, pp. 2434–2450, 2013. View at: Publisher Site | Google Scholar
  4. I. Kostova, S. Bhatia, P. Grigorov et al., “Coumarins as antioxidants,” Current Medicinal Chemistry, vol. 18, no. 25, pp. 3929–3951, 2011. View at: Publisher Site | Google Scholar
  5. J.-Y. Yeh, M. S. Coumar, J.-T. Horng et al., “Anti-influenza drug discovery: structure−activity relationship and mechanistic insight into novel angelicin derivatives,” Journal of Medicinal Chemistry, vol. 53, no. 4, pp. 1519–1533, 2010. View at: Publisher Site | Google Scholar
  6. K. V. Sashidhara, A. Kumar, M. Chatterjee et al., “Discovery and synthesis of novel 3-phenylcoumarin derivatives as antidepressant agents,” Bioorganic & Medicinal Chemistry Letters, vol. 21, no. 7, pp. 1937–1941, 2011. View at: Publisher Site | Google Scholar
  7. J. Neyts, E. D. Clercq, R. Singha et al., “Structure−activity relationship of new anti-hepatitis C virus agents: heterobicycle−Coumarin conjugates,” Journal of Medicinal Chemistry, vol. 52, no. 5, pp. 1486–1490, 2009. View at: Publisher Site | Google Scholar
  8. G. Melagraki, A. Afantitis, O. Igglessi-Markopoulou et al., “Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts,” European Journal of Medicinal Chemistry, vol. 44, no. 7, pp. 3020–3026, 2009. View at: Publisher Site | Google Scholar
  9. S. H. Cardoso, M. B. Barreto, M. C. S. Lourenço et al., “Antitubercular activity of new coumarins,” Chemical Biology & Drug Design, vol. 77, no. 6, pp. 489–493, 2011. View at: Publisher Site | Google Scholar
  10. K. M. Khan, F. Rahim, A. Wadood et al., “Synthesis and molecular docking studies of potent α-glucosidase inhibitors based on biscoumarin skeleton,” European Journal of Medicinal Chemistry, vol. 81, pp. 245–252, 2014. View at: Publisher Site | Google Scholar
  11. I. Manolov, C. Maichle-Moessmer, I. Nicolova, and N. Danchev, “Synthesis and anticoagulant activities of substituted 2,4-diketochromans, biscoumarins, and chromanocoumarins,” Archiv der Pharmazie, vol. 339, no. 6, pp. 319–326, 2006. View at: Publisher Site | Google Scholar
  12. N. Hamdi, M. C. Puerta, and P. Valerga, “Synthesis, structure, antimicrobial and antioxidant investigations of dicoumarol and related compounds,” European Journal of Medicinal Chemistry, vol. 43, no. 11, pp. 2541–2548, 2008. View at: Publisher Site | Google Scholar
  13. C.-X. Su, J.-F. Mouscadet, C.-C. Chiang, H.-J. Tsai, and L.-Y. Hsu, “HIV-1 integrase inhibition of biscoumarin analogues,” Chemical & Pharmaceutical Bulletin, vol. 54, no. 5, pp. 682–686, 2006. View at: Publisher Site | Google Scholar
  14. M. A. Lodhi, Z. ul-Haq, A. Wadood et al., “Three-dimensional quantitative structure–activity relationship (CoMSIA) analysis of bis-coumerine analogues as urease inhibitors,” Medicinal Chemistry Research, vol. 22, pp. 498–504, 2013. View at: Google Scholar
  15. M. Faisal, A. Saeed, D. Shahzad et al., “Enzyme inhibitory activities an insight into the structure-activity relationship of biscoumarin derivatives,” European Journal of Medicinal Chemistry, vol. 141, pp. 386–403, 2017. View at: Publisher Site | Google Scholar
  16. Y.-P. Sui, H.-R. Huo, J.-J. Xin et al., “Antibacterial and antitumor activities of biscoumarin and dihydropyran derivatives,” Molecules, vol. 20, no. 9, pp. 17614–17626, 2015. View at: Publisher Site | Google Scholar
  17. V. D. Kancheva, P. V. Boranova, J. T. Nechev, and I. I. Manolov, “Structure-activity relationships of new 4-hydroxy bis-coumarins as radical scavengers and chain-breaking antioxidants,” Biochimie, vol. 92, no. 9, pp. 1138–1146, 2010. View at: Publisher Site | Google Scholar
  18. J. Xu, J. Ai, S. Liu et al., “Design and synthesis of 3,3-biscoumarin-based c-Met inhibitors,” Organic and Biomolecular Chemistry, vol. 12, no. 22, pp. 3721–3734, 2014. View at: Publisher Site | Google Scholar
  19. F. G. Medina, J. G. Marrero, M. Macías-Alonso et al., “Coumarin heterocyclic derivatives: chemical synthesis and biological activity,” Natural Product Reports, vol. 32, no. 10, pp. 1472–1507, 2015. View at: Publisher Site | Google Scholar
  20. J.-C. Jung, Y.-J. Jung, and O.-S. Park, “A convenient one-pot synthesis of 4-hydroxycoumarin, 4-hydroxythiocoumarin, and 4-hydroxyquinolin-2(1H)-one,” Synthetic Communications, vol. 31, no. 8, pp. 1195–1200, 2001. View at: Publisher Site | Google Scholar
  21. J.-C. Jung, J.-H. Lee, S. Oh, J.-G. Lee, and O.-S. Park, “Synthesis and antitumor activity of 4-hydroxycoumarin derivatives,” Bioorganic & Medicinal Chemistry Letters, vol. 14, no. 22, pp. 5527–5531, 2004. View at: Publisher Site | Google Scholar
  22. M. Himly, B. Jahn-Schmid, K. Pittertschatscher et al., “IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone,” Journal of Allergy and Clinical Immunology, vol. 111, no. 4, pp. 882–888, 2003. View at: Publisher Site | Google Scholar
  23. Y. Okamoto, M. Ojika, S. Kato, and Y. Sakagami, “Ianthesines A-D, four novel dibromotyrosine-derived metabolites from a marine sponge, Lanthella sp.,” Tetrahedron, vol. 56, no. 32, pp. 5813–5818, 2000. View at: Publisher Site | Google Scholar
  24. M. A. Al-Haiza, S. A. El-Assiery, and G. H. Sayed, “Synthesis and potential antimicrobial activity of some new compounds containing the pyrazol-3-one moiety,” Acta Pharmaceutica, vol. 51, pp. 251–261, 2001. View at: Google Scholar
  25. M. Radi, V. Bernardo, B. Bechi, D. Castagnolo, M. Pagano, and M. Botta, “Microwave-assisted organocatalytic multicomponent knoevenagel/hetero diels-alder reaction for the synthesis of 2,3-dihydropyran[2,3-c]pyrazoles,” Tetrahedron Letters, vol. 50, no. 47, pp. 6572–6575, 2009. View at: Publisher Site | Google Scholar
  26. F. Moreau, N. Desroy, J. M. Genevard et al., “Discovery of new Gram-negative antivirulence drugs: structure and properties of novel E. coli waaC inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 14, pp. 4022–4026, 2008. View at: Publisher Site | Google Scholar
  27. A. Dömling, “Recent developments in isocyanide based multicomponent reactions in applied chemistry,” Chemical Reviews, vol. 106, no. 1, pp. 17–89, 2006. View at: Publisher Site | Google Scholar
  28. J.-J. Wang, X. Feng, Z. Xun, D.-Q. Shi, and Z.-B. Huang, “Multicomponent Strategy to Pyrazolo[3,4-e]indolizine derivatives under microwave irradiation,” Journal of Organic Chemistry, vol. 80, no. 16, pp. 8435–8442, 2015. View at: Publisher Site | Google Scholar
  29. N. M. Ghohe, R. Tayebee, and M. M. Amini, “Synthesis and characterization of mesoporous Nb–Zr/KIT-6 as a productive catalyst for the synthesis of benzylpyrazolyl coumarins materials,” Chemistry and Physics, vol. 223, pp. 268–276, 2019. View at: Publisher Site | Google Scholar
  30. T. A. J. Siddiqui, B. G. Ghule, S. Shaikh et al., “Metal-free heterogeneous and mesoporous biogenic graphene-oxide nanoparticle-catalyzed synthesis of bioactive benzylpyrazolyl coumarin derivatives,” RSC Advances, vol. 8, no. 31, pp. 17373–17379, 2018. View at: Publisher Site | Google Scholar
  31. H. Wang, X. Liu, X. Feng, Z. Huang, and D. Shi, “GAP chemistry for pyrrolyl coumarin derivatives: a highly efficient one-pot synthesis under catalyst-free conditions,” Green Chemistry, vol. 15, no. 12, pp. 3307–3311, 2013. View at: Publisher Site | Google Scholar
  32. A. Saha, S. Payra, and S. Banerjee, “One-pot multicomponent synthesis of highly functionalized bio-active pyrano[2,3-c]pyrazole and benzylpyrazolyl coumarin derivatives using ZrO2 nanoparticles as a reusable catalyst,” Green Chemistry, vol. 17, no. 5, pp. 2859–2866, 2015. View at: Publisher Site | Google Scholar
  33. P. G. Partha, P. Gargi, P. Sanjay, and R. Asish, “Design and synthesis of benzylpyrazolyl coumarin derivatives via a four-component reaction in water: investigation of the weak interactions accumulating in the crystal structure of a signified compound,” Green Chemistry, vol. 14, no. 2691, 2012. View at: Google Scholar
  34. S. Yaragorla, A. Pareek, and R. Dada, “Ca(II)-catalyzed, one-pot four component synthesis of functionally embellished benzylpyrazolyl coumarins in water,” Tetrahedron Letters, vol. 56, no. 33, pp. 4770–4774, 2015. View at: Publisher Site | Google Scholar
  35. A. Saha, S. Payra, S. K. Verma, M. Mandal, S. Thareja, and S. Banerjee, “In silico binding affinity to cyclooxygenase-II and green synthesis of benzylpyrazolyl coumarin derivatives,” RSC Advances, vol. 5, no. 122, pp. 100978–100983, 2015. View at: Publisher Site | Google Scholar
  36. N. Touj, A. Chakchouk-Mtibaa, L. Mansour et al., “Copper-catalyzed azide-alkyne cycloaddition (CuAAC) under mild condition in water: synthesis, catalytic application and biological activities,” Journal of Organometallic Chemistry, vol. 853, pp. 49–63, 2017. View at: Publisher Site | Google Scholar
  37. N. Hamdi, R. Medyouni, H. Bilel, L. Mansour, and A. Romerosa, “An efficient one-pot protocol for the synthesis of substituted 3,4-dihydropyrimidin-2(1H)-ones using metallophthalocyanines (MPcs) as potent heterogeneous catalysts: synthesis, characterization, aggregation and antimicrobial activity,” Molecules, vol. 22, no. 4, pp. 605–619, 2017. View at: Publisher Site | Google Scholar

Copyright © 2019 Hamida Jelali et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

691 Views | 357 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.